New Treatments For Rheumatoid Arthritis (6/18/2007)
Three new drugs mark a new era for rheumatoid arthiritis treatment, according to work by an international research team including Professor Paul Emery from the University of Leeds. Their findings are published in the Lancet today (June 13).
The team studied rituximab, abatacept and tocilizumab and examined their effects as sole therapies and their effectiveness when combined with existing treatments. They looked at the how the disease develops and other potential approaches to treatment and also provided a comprehensive overview on ways to assess treatment response.
The authors concluded all three new drugs diminish signs and symptoms of rheumatoid arthritis and improve physical function and health status, and retard progression of joint damage—thus expanding the range of treatments to fight rheumatoid arthritis. The disease is the most common of all chronic inflammatory joint diseases, affecting around one in fifty people in the UK*. Typical symptoms are joint pain, stiffness, and swelling which over time, your joints become damaged and stop working properly.
See The Lancet, www.lancet.com for more information and the full paper.
Note: This story has been adapted from a news release issued by the University of Leeds
Personal Loans - Car Insurance - Credit Counseling - Homeowner Loans
Post Comments:
| 
Subscribe
